SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 116 filers reported holding SUTRO BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,102,123 | -22.9% | 1,182,168 | +3.3% | 0.75% | -18.4% |
| Q2 2023 | $5,318,954 | +4.7% | 1,143,861 | +4.0% | 0.92% | -16.6% |
| Q1 2023 | $5,082,176 | -27.4% | 1,100,038 | +27.0% | 1.10% | -40.7% |
| Q4 2022 | $6,997,078 | +83.4% | 865,975 | +26.0% | 1.86% | +71.7% |
| Q3 2022 | $3,815,000 | +297.0% | 687,335 | +272.5% | 1.08% | +206.5% |
| Q2 2022 | $961,000 | -41.5% | 184,518 | -7.7% | 0.35% | -26.4% |
| Q1 2022 | $1,643,000 | -50.1% | 199,846 | -9.7% | 0.48% | -33.7% |
| Q4 2021 | $3,292,000 | +6.7% | 221,219 | +35.4% | 0.73% | -7.0% |
| Q3 2021 | $3,086,000 | +1.6% | 163,389 | 0.0% | 0.78% | +17.6% |
| Q2 2021 | $3,037,000 | -34.2% | 163,389 | -19.4% | 0.66% | -38.0% |
| Q1 2021 | $4,613,000 | -20.3% | 202,696 | -24.0% | 1.07% | -27.8% |
| Q4 2020 | $5,789,000 | +174.2% | 266,645 | +27.0% | 1.48% | +165.3% |
| Q3 2020 | $2,111,000 | – | 210,000 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
| Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
| Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
| Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
| BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
| DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
| SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
| Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
| Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |